Market Overview

Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

Related AMGN
EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
Premarket Biotech Digest: Clovis A Buy, Cellceutix Rallies, Pfizer's Avelumab Milestone (Seeking Alpha)

Analysts at Jefferies on Friday, March 28, 2014, released a new price target regarding Amgen (NASDAQ: AMGN).

Equity analyst Eun K. Yang at Jefferies led the research and raised their price target from $138.00 to $145.00 per share.

From the 48 cardiologists' surveys taken, Jefferies is increasing its United States and European Union sales estimates for 2017-2020 by 22 to 49 percent. According to Jefferies, this new estimate reflects its broad use in hypercholesterolemia.

Jefferies now estimates sales to be at approximately $1.7 billion in 2019, this is up $0.5 billion from its estimate of $1.2 billion.

The price target issued by Jefferies is based on:

• P/E multiple of ~16x (2015 P/E for big pharma) to our 2015 EPS forecast of $9.26, discounting at 10 percent. • Sum-of-the parts NPV analysis. Risks associated with Amgen include pricing pressure, competition and regulatory delays/failure of evolocumab (AMG-145)

Shares of Amgen are currently trading at $120.55 as of Friday, March 28, 2014.

Latest Ratings for AMGN

Nov 2015Piper JaffrayUpgradesOverweight
Sep 2015NomuraMaintainsBuy
Sep 2015UBSUpgradesNeutralBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Eun K. Yang JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (AMGN)

Get Benzinga's Newsletters